Ani Pharmaceuticals (ANIP) Current Assets (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Current Assets data on file, last reported at $747.1 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 39.31% year-over-year to $747.1 million; the trailing twelve-month figure through Mar 2026 stood at $747.1 million (up 39.31% YoY), and the FY2025 full-year result was $753.1 million, up 42.51% from the prior year.
• Current Assets declined to $747.1 million in Q1 2026, from $753.1 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $753.1 million in Q4 2025 to a low of $301.4 million in Q1 2022.
• A 5-year average of $506.0 million and a median of $521.3 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets surged 68.09% in 2022 and dropped 0.79% in 2025, its largest moves.
• Tracing ANIP's Current Assets over 5 years: stood at $344.3 million in 2022, then jumped by 50.99% to $519.8 million in 2023, then rose by 1.66% to $528.5 million in 2024, then jumped by 42.51% to $753.1 million in 2025, then fell by 0.8% to $747.1 million in 2026.
• Business Quant data shows ANIP's Current Assets at $747.1 million in Q1 2026, $753.1 million in Q4 2025, and $698.4 million in Q3 2025.